JAIME PHILLIPS: Open Payments
NPI 1679190532 · MANCHESTER, TN. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$865 in 41 payments from 10 companies in 2025. Trend: 2023 $803 · 2024 $801 · 2025 $865
Food & beverage: $865
| Company | Payments | Amount |
|---|---|---|
| Neurocrine BioSciences, Inc. | 9 | $239 |
| Alkermes, Inc. | 9 | $193 |
| ABBVIE INC. | 4 | $89 |
| E.R. Squibb & Sons, L.L.C. | 4 | $74 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | 4 | $64 |
| Teva Pharmaceuticals USA, Inc. | 3 | $62 |
| Lundbeck LLC | 3 | $59 |
| Otsuka America Pharmaceutical, Inc. | 3 | $50 |
| Braeburn Inc. | 1 | $19 |
| Axsome Therapeutics, Inc. | 1 | $17 |
Products named: INGREZZA, ARISTADA, REXULTI, VRAYLAR, COBENFY, CAPLYTA, AUSTEDO XR, LYBALVI.
Industry payments across TN — which companies pay providers there.
